Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 639-657 , August 2008

Acromegaly, growth hormone and cancer risk

  • Andrew G. Renehan, PhD, FRCS (Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Surgery, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Tel.: +44 161 446 3157; Fax: +44 161 446 3365.

References 

  1. Renehan AG, O'Connell J, O'Halloran D, et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and Metabolic Research. 2003;35(11–12):70–81
  2. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews. 2004;25(1):102–152
  3. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends in Molecular Medicine. 2001;7(10):447–454
  4. Sperling MA, Saenger PH, Ray H, et al. Growth hormone treatment and neoplasia-coincidence or consequence?. The Journal of Clinical Endocrinology and Metabolism. 2002;87(12):5351–5352
  5. Renehan AG. Cancer risk and the growth hormone/IGF-I axis. In:  Ross R,  Erfurth EM editor. Pituitary function through the ages. HypoCCS Series. Bristol: BioScientific; 2004;p. 143–177
  6. Shalet SM, Brennan BM. Growth and growth hormone status following treatment for childhood leukaemia. Hormone Research. 1998;50(1):1–10
  7. Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Hormone Research. 1997;48(Suppl. 4):29–32
  8. Klein I, Parveen G, Gavaler JS, et al. Colonic polyps in patients with acromegaly. Annals of Internal Medicine. 1982;97(1):27–30
  9. Ituarte EM, Petrini J, Hershman JM. Acromegaly and colon cancer. Annals of Internal Medicine. 1984;101(5):627–628
  10. Brunner JE, Johnson CC, Zafar S, et al. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clinical Endocrinology. 1990;32(1):65–71
  11. Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly. Annals of Internal Medicine. 1991;114(9):754–755
  12. Ortego J, Vega B, Sampedro J, et al. Neoplastic colonic polyps in acromegaly. Hormone and Metabolic Research. 1994;26(12):609–610
  13. Ladas SD, Thalassinos NC, Ioannides G, et al. Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours?. Clinical Endocrinology. 1994;41(5):597–601
  14. Vasen HF, van Erpecum KJ, Roelfsema F, et al. Increased prevalence of colonic adenomas in patients with acromegaly. European Journal of Endocrinology. 1994;131(3):235–237
  15. Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. [see comments] The Journal of Clinical Endocrinology and Metabolism. 1995;80(11):3223–3226
  16. Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clinical Endocrinology. 1997;47(1):17–22
  17. Renehan AG, O'Dwyer ST, Shalet SM. Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. Gut. 2000;46(3):440–441
  18. Martino A, Cammarota G, Cianci R, et al. High prevalence of hyperplastic colonic polyps in acromegalic subjects. Digestive Diseases and Sciences. 2004;49(4):662–666
  19. Bhansali A, Kochhar R, Chawla YK, et al. Prevalence of colonic polyps is not increased in patients with acromegaly: analysis of 60 patients from India. Journal of Gastroenterology and Hepatology. 2004;19(3):266–269
  20. Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. The Journal of Clinical Endocrinology and Metabolism. 2005;90(1):84–90
  21. Matano Y, Okada T, Suzuki A, et al. Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels. The American Journal of Gastroenterology. 2005;100(5):1154–1160
  22. Matyja V, Kos-Kudla B, Foltyn W, et al. Detection of colorectal lesions by using autofluorescence colonoscopy in acromegalics and their relation to serum growth hormone and insulin-like growth factor-1 levels. Neuro Endocrinology Letters. 2006;27(5):639–643
  23. Jenkins PJ, Besser GM, Fairclough PD. Colorectal neoplasia in acromegaly. Gut. 1999;44(5):585–587
  24. Renehan AG, O'Dwyer ST, Shalet SM. Screening colonoscopy for acromegaly in perspective. Clinical Endocrinology. 2001;55(6):731–733
  25. Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. The Journal of Clinical Endocrinology and Metabolism. 2002;87(4):
  26. Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer. 1991;68(8):1673–1677
  27. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. The Journal of Clinical Endocrinology and Metabolism. 1998;83(8):2730–2734
  28. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395–400
  29. Kurimoto M, Fukuda I, Hizuka N, et al. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocrine Journal. 2008;55(1):67–71
  30. Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Reviews in Endocrine & Metabolic Disorders. 2008;9(1):41–58
  31. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer?. Clinical Endocrinology. 2006;64(2):115–121
  32. Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary. 2002;5(1):21–25
  33. Pollak M. Insulin-like growth factor physiology and cancer risk. European Journal of Cancer. 2000;36(10):1224–1228
  34. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews. Cancer. 2004;4(7):505–518
  35. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–1353
  36. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiology, Biomarkers & Prevention. 2000;9(4):345–349
  37. Renehan AG, Painter JE, Atkin WS, et al. High-risk colorectal adenomas and serum insulin-like growth factors. The British Journal of Surgery. 2001;88(1):107–113
  38. Teramukai S, Rohan T, Lee KY, et al. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Japanese Journal of Cancer Research : Gann. 2002;93(11):1187–1194
  39. Paterson AC, Leeding KS, Bach LA, et al. More about: prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute. 2000;92(23):1947–1950
  40. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Letters. 2003;195(2):127–137
  41. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews. 2000;21(3):215–244
  42. Adenis A, Peyrat JP, Hecquet B, et al. Type I insulin-like growth factor receptors in human colorectal cancer. European Journal of Cancer. 1995;31a(1):50–55
  43. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene. 2001;20(2):252–259
  44. Playford MP, Bicknell D, Bodmer WF, et al. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(22):12103–12108
  45. Renehan AG, Bhaskar P, Painter JE, et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2000;85(9):3417–3424
  46. Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2000;85(9):3218–3221
  47. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute. 2005;97(22):1679–1687
  48. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. The Journal of Nutrition. 2001;131(11 Suppl):3109S–3120S
  49. Stoll BA. Association between breast and colorectal cancers. The British Journal of Surgery. 1998;85(11):1468–1472
  50. Colao A, Pivonello R, Auriemma RS, et al. The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. The Journal of Clinical Endocrinology and Metabolism. 2007;92(10):3854–3860
  51. Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia?. The Journal of Clinical Endocrinology and Metabolism. 1991;72(2):245–249
  52. Ziel FH, Peters AL. Acromegaly and gastrointestinal adenocarcinomas. Annals of Internal Medicine. 1988;109(6):514–515
  53. Sonksen P, Jacobs H, Orme S, et al. Acromegaly and colonic cancer. Clinical Endocrinology. 1997;47(6):647–648
  54. de Herder WW, van der Lely AJ, Lamberts SW. Colorectal cancer screening in acromegaly. Still many unresolved questions. [comment] Clinical Endocrinology. 1997;47(6):644–646
  55. Jenkins PJ, Fairclough PD. Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut. 2002;51(Suppl. 5):V13–V14
  56. Renehan AG, O'Dwyer ST, Shalet SM. Guidelines for colonoscopic screening in acromegaly are inconsistent with those for other high risk groups. Gut. 2003;52(7):1071–1072
  57. Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut. 2002;51(Suppl. 5):V21–V27
  58. Dunlop MG. Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer or one first degree relative diagnosed with colorectal cancer under 45 years. Gut. 2002;51(Suppl. 5):V17–V20
  59. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570–1595
  60. Renehan AG, Painter JE, Bell GD, et al. Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clinical Endocrinology. 2005;62(3):323–330
  61. Mertani HC, Garcia-Caballero T, Lambert A, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. International Journal of Cancer. 1998;79(2):202–211
  62. Kaulsay KK, Zhu T, Bennett W, et al. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology. 2001;142(2):767–777
  63. Tornell J, Carlsson B, Pohjanen P, et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. The Journal of Steroid Biochemistry and Molecular Biology. 1992;43(1–3):237–242
  64. Yang XF, Beamer WG, Huynh H, et al. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Research. 1996;56(7):1509–1511
  65. Ng ST, Zhou J, Adesanya OO, et al. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Medicine. 1997;3(10):1141–1144
  66. Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. The Journal of Clinical Endocrinology and Metabolism. 1998;83(3):775–779
  67. Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism. 1999;84(1):17–23
  68. Tita P, Ambrosio MR, Scollo C, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clinical Endocrinology. 2005;63(2):161–167
  69. Renehan A, Tyson M, Egger M, et al. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578
  70. Taback SP, Dean HJ. Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967–1992. The Canadian Growth Hormone Advisory Committee. The Journal of Clinical Endocrinology and Metabolism. 1996;81(5):1693–1696
  71. Arslanian SA, Becker DJ, Lee PA, et al. Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism. American Journal of Diseases of Children (1911). 1985;139(4):347–350
  72. Rodens KP, Kaplan SL, Grumbach MM, et al. Growth hormone therapy and tumor recurrence. Findings in children with brain tumors?. Acta Endocrinologica. 1987;283(suppl):188–189
  73. Clayton PE, Shalet SM, Gattamaneni HR, et al. Does growth hormone cause relapse of brain tumours?. Lancet. 1987;1(8535):711–713
  74. Ogilvy-Stuart AL, Ryder WD, Gattamaneni HR, et al. Growth hormone and tumour recurrence. BMJ (Clinical Research Ed.). 1992;304(6842):1601–1605
  75. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. The Journal of Clinical Endocrinology and Metabolism. 2000;85(12):4444–4449
  76. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. The Journal of Clinical Endocrinology and Metabolism. 2002;87(7):3136–3141
  77. Leung W, Rose SR, Zhou Y, et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 2002;20(13):2959–2964
  78. Jostel A, Mukherjee A, Hulse PA, et al. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clinical Endocrinology. 2005;62(6):698–705
  79. Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clinical Endocrinology. 2006;64(5):556–560
  80. Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. The Journal of Pediatrics. 2004;144(4):430–436
  81. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. The Journal of Clinical Endocrinology and Metabolism. 2006;91(9):3494–3498
  82. Wada E, Murata M, Watanabe S. Acute lymphoblastic leukemia following treatment with human growth hormone in a boy with possible preanemic Fanconi's anemia. Japanese Journal of Clinical Oncology. 1989;19(1):36–39
  83. Fradkin JE, Mills JL, Schonberger LB, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA : The Journal of the American Medical Association. 1993;270(23):2829–2832
  84. Allen DB, Rundle AC, Graves DA, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis. The Journal of Pediatrics. 1997;131(1 Pt 2):S32–S36
  85. Tuffli GA, Johanson A, Rundle AC, et al. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. The Journal of Clinical Endocrinology and Metabolism. 1995;80(4):1416–1422
  86. Nishi Y, Tanaka T, Takano K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. The Journal of Clinical Endocrinology and Metabolism. 1999;84(6):1961–1965
  87. Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 2002;360(9329):273–277
  88. Svensson J, Bengtsson BA, Rosen T, et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. The Journal of Clinical Endocrinology and Metabolism. 2004;89(7):3306–3312
  89. Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. The Journal of Clinical Endocrinology and Metabolism. 2005;90(9):5247–5253
  90. Attanasio AF, Bates PC, Ho KK, et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status–3-year results from the HypoCCS Database. The Journal of Clinical Endocrinology and Metabolism. 2002;87(4):1600–1606
  91. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. The Journal of Clinical Endocrinology and Metabolism. 2001;86(10):4657–4665
  92. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology. 2003;148(Suppl. 2):S9–S14
  93. Berster JM, Goke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Archives of Physiology and Biochemistry. 2008;114(1):84–98
  94. Shalet SM, Toogood A, Rahim A, et al. The diagnosis of growth hormone deficiency in children and adults. Endocrine Reviews. 1998;19(2):203–223
  95. Woodhouse LJ, Mukherjee A, Shalet SM, et al. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocrine Reviews. 2006;27(3):287–317
  96. Swerdlow AJ. Design and interpretation of studies of the risk of cancer and other long-term morbidity and mortality after growth hormone treatment. Growth Hormone & IGF Research. 2000;10(6):318–323

PII: S1521-690X(08)00097-3

doi: 10.1016/j.beem.2008.08.011

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 639-657 , August 2008

Article Tools

* Image Usage & Resolution